Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Other Non-Current Liabilities (2023 - 2026)

Beta Bionics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 289.5% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 million, a 289.5% increase, with the full-year FY2025 number at $1.5 million, down 96.55% from a year prior.
  • Other Non-Current Liabilities hit $1.6 million in Q1 2026 for Beta Bionics, up from $1.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for BBNX hit a ceiling of $44.9 million in Q4 2024 and a floor of $400000.0 in Q1 2025.
  • Historically, Other Non-Current Liabilities has averaged $10.4 million across 4 years, with a median of $1.5 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 96.55% in 2025 and later surged 289.5% in 2026.
  • Tracing BBNX's Other Non-Current Liabilities over 4 years: stood at $22.3 million in 2023, then soared by 101.15% to $44.9 million in 2024, then crashed by 96.55% to $1.5 million in 2025, then rose by 0.71% to $1.6 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for BBNX at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.